JP2005510211A - 合成ｈｃｖ外被蛋白質及びワクチンのためのその使用 - Google Patents

合成ｈｃｖ外被蛋白質及びワクチンのためのその使用 Download PDF

Info

Publication number
JP2005510211A
JP2005510211A JP2003526952A JP2003526952A JP2005510211A JP 2005510211 A JP2005510211 A JP 2005510211A JP 2003526952 A JP2003526952 A JP 2003526952A JP 2003526952 A JP2003526952 A JP 2003526952A JP 2005510211 A JP2005510211 A JP 2005510211A
Authority
JP
Japan
Prior art keywords
hcv
protein
composition
introducing
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2003526952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005510211A5 (https=
Inventor
ネヴィル、ルイス
ザウベルマン、アリー
Original Assignee
エックステイエル バイオファーマスーティカルズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エックステイエル バイオファーマスーティカルズ リミテッド filed Critical エックステイエル バイオファーマスーティカルズ リミテッド
Publication of JP2005510211A publication Critical patent/JP2005510211A/ja
Publication of JP2005510211A5 publication Critical patent/JP2005510211A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2003526952A 2001-09-13 2002-09-09 合成ｈｃｖ外被蛋白質及びワクチンのためのその使用 Abandoned JP2005510211A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14544001A IL145440A0 (en) 2001-09-13 2001-09-13 Synthetic hcv envelope proteins and their use for vaccination
PCT/IL2002/000744 WO2003022880A2 (en) 2001-09-13 2002-09-09 Synthetic hcv envelope proteins and their use for vaccination

Publications (2)

Publication Number Publication Date
JP2005510211A true JP2005510211A (ja) 2005-04-21
JP2005510211A5 JP2005510211A5 (https=) 2006-01-05

Family

ID=11075784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003526952A Abandoned JP2005510211A (ja) 2001-09-13 2002-09-09 合成ｈｃｖ外被蛋白質及びワクチンのためのその使用

Country Status (8)

Country Link
US (1) US20050069865A1 (https=)
EP (1) EP1427827A2 (https=)
JP (1) JP2005510211A (https=)
KR (1) KR20040041612A (https=)
CN (1) CN1555415A (https=)
CA (1) CA2460509A1 (https=)
IL (1) IL145440A0 (https=)
WO (1) WO2003022880A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1846439A2 (en) * 2005-01-31 2007-10-24 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
EP2061805B1 (en) 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein
US9758794B2 (en) * 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
WO2009146902A1 (en) * 2008-06-03 2009-12-10 Okairòs Ag A vaccine for the prevention and therapy of hcv infections
US9512184B2 (en) 2011-05-20 2016-12-06 Emory University Hepatitis C virus particles, vaccines, compositions and methods related thereto
CN105330730A (zh) * 2014-07-29 2016-02-17 中国科学院上海巴斯德研究所 一种丙型肝炎病毒重组蛋白的制备及其应用
CN116768983A (zh) * 2020-10-28 2023-09-19 王立良 一种用于慢性乙型肝炎预防和/或治疗的蛋白、编码基因、重组腺相关病毒及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849987A (en) * 1992-06-02 1998-12-15 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection

Also Published As

Publication number Publication date
EP1427827A2 (en) 2004-06-16
IL145440A0 (en) 2002-06-30
CA2460509A1 (en) 2003-03-20
US20050069865A1 (en) 2005-03-31
KR20040041612A (ko) 2004-05-17
CN1555415A (zh) 2004-12-15
WO2003022880A3 (en) 2003-10-09
WO2003022880A2 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
JP2656995B2 (ja) Ｎａｎｂｖの診断用薬
CA2065287C (en) New hcv isolates
JP3892443B2 (ja) 診断用及び治療用の精製ｃ型肝炎ウイルスエンベロープ蛋白
Tsukiyama-Kohara et al. Antigenicities of group I and II hepatitis C virus polypeptides—molecular basis of diagnosis
JP2532805B2 (ja) Ｎａｎｂｖの診断用薬およびワクチン
JP5829830B2 (ja) Ｅ型肝炎ウイルスのポリペプチド断片、それを含むワクチン組成物及び診断キット、並びにその使用
US5766840A (en) Hepatitis G virus and molecular cloning thereof
KR100394693B1 (ko) G형 간염바이러스 및 이것의 분자클로닝 방법
Hsu et al. Characterization of hepatitis C virus structural proteins with a recombinant baculovirus expression system
CZ294629B6 (cs) Způsob klasifikace typů hepatitis C viru, polypeptid a kompozice pro použití ve způsobu
JP2007513604A (ja) 新規エンテロウイルス、ワクチン、医薬および診断キット
CN1768078B (zh) 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物
JP2005510211A (ja) 合成ｈｃｖ外被蛋白質及びワクチンのためのその使用
JP4641695B2 (ja) 新規なｈｅｖ抗原性ペプチド及び方法
CN100497377C (zh) Sars冠状病毒结构蛋白orf3及其应用
AU2002329033A1 (en) Synthetic HCV envelope proteins and their use for vaccination
KR0120928B1 (ko) 한국에서 분리한 신규한 c형 바이러스 유전자
JPH08504421A (ja) Ｈｃｖのｃ３３領域由来のペプチド、該ペプチドに対する抗体及びｈｃｖの検出方法
Timofeev et al. A study of the NS3 nonstructural protein of tick-borne encephalitis virus using monoclonal antibodies against the virus
KR100946170B1 (ko) 항 ｎｓ５ｂ 항체를 포함하는 ｃ형 간염 바이러스 매개간질환 예방 및 치료제
KR100187483B1 (ko) Hcv 폴리뉴클레오티드 및 그 사용
Park et al. Characterization of Monoclonal Antibody Specific for Hepatitis C Virus E2 Envelope Protein
JPH08505131A (ja) 肝炎ｃ型ウイルス（ｈｃｖ）非構造−３−ペプチド、該ペプチドに対する抗体及びｈｃｖの検出方法
JP2004525885A (ja) 診断用および治療用の精製ｃ型肝炎ウイルスエンベロープタンパク質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050830

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20061124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061124